Biogen (LTS:0R1B) Total Tax Payable : $231 Mil (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Biogen Total Tax Payable?

Biogen's Total Tax Payable for the quarter that ended in Mar. 2024 was $231 Mil.

Biogen's quarterly Total Tax Payable increased from Sep. 2023 ($244 Mil) to Dec. 2023 ($257 Mil) but then declined from Dec. 2023 ($257 Mil) to Mar. 2024 ($231 Mil).

Biogen's annual Total Tax Payable increased from Dec. 2021 ($175 Mil) to Dec. 2022 ($260 Mil) but then declined from Dec. 2022 ($260 Mil) to Dec. 2023 ($257 Mil).

Biogen Total Tax Payable Historical Data

The historical data trend for Biogen's Total Tax Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Total Tax Payable Chart

Biogen Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Tax Payable

Get a 7-Day Free Trial

71.40

142.00

174.70

259.90

257.40

Biogen Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Tax Payable	Get a 7-Day Free Trial															235.50	260.00	243.80	257.40	231.20

Biogen Total Tax Payable Calculation

Total Tax Payable is the taxes liability owed to federal, state, and local tax authorities. It is the carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes.

Biogen Total Tax Payable Related Terms

Thank you for viewing the detailed overview of Biogen's Total Tax Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Biogen (LTS:0R1B) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (LTS:0R1B) » Definitions » Total Tax Payable

Comparable Companies

Traded in Other Exchanges

BIIB:USA BIIB:Mexico 1BIIB:Italy IDP:Germany BIIB34:Brazil BIIB:Austria BIIB:Argentina

Address

225 Binney Street, Cambridge, MA, USA, 02142

Website

https://www.biogen.com

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.

Biogen (LTS:0R1B) Headlines

No Headlines